Cellebrite DI Ltd. $CLBT Stock Position Lowered by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich reduced its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 35.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 225,880 shares of the company’s stock after selling 126,235 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich owned 0.09% of Cellebrite DI worth $3,697,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Signaturefd LLC lifted its position in Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares in the last quarter. Assetmark Inc. bought a new position in Cellebrite DI during the first quarter valued at about $33,000. PNC Financial Services Group Inc. grew its holdings in Cellebrite DI by 1,998.0% during the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after purchasing an additional 1,998 shares during the last quarter. Virtus Advisers LLC acquired a new stake in shares of Cellebrite DI in the first quarter valued at about $63,000. Finally, Hennessy Advisors Inc. acquired a new stake in shares of Cellebrite DI in the second quarter worth $83,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Down 3.2%

Cellebrite DI stock opened at $16.88 on Friday. The stock has a market cap of $4.04 billion, a PE ratio of -22.21, a P/E/G ratio of 3.16 and a beta of 1.28. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The business’s 50-day moving average price is $17.88 and its two-hundred day moving average price is $16.62.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million during the quarter, compared to the consensus estimate of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm’s revenue was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.14 earnings per share. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on CLBT shares. Bank of America upped their target price on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Wednesday. Lake Street Capital boosted their price objective on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Needham & Company LLC upped their price target on Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.